Business - Briefly   

Ranbaxy's in-licensing pact with Dutch firm

GURGAON (Haryana) : Ranbaxy Laboratories announced on Wednesday that it had entered into an in-licensing agreement for the Indian market, with the Netherlands-based pharma company, Eurodrug Laboratories, for the asthma product doxophylline, a novel xanthine bronchodilator. The product, developed in collaboration with many European medical centres, will be introduced for the first time in India under the brand name `Synasma', according to a Ranbaxy release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Mauritius textiles, sugar to get duty-free entry
Airbus Industrie to set up MRO facility in India
`Oil PSUs losing $51 m a day'
HSCI to double capacity
Lifetime Healthcare to focus on spreading wings in south
Eveready to extend brand to other FMCG segments
Maples opens second centre in Chennai
CAMPCO's areca nut unit earns Rs.21- cr. profit
JRG completes listing formalities with BSE
Smart rally in Sensex
Rupee gains 32 paise
Exchange rates
Bullion rates
Mittal Steel to launch offer today
RRBs to market mutual funds
Gairola new CMD of Dena Bank
L&T ventures into dredging
Gates Foundation sells stake in India Fund
Rathi Udyog fixes price band
Ranbaxy's in-licensing pact with Dutch firm
Elder Pharma ties up with Sterisol
Jain Granites bags Rs. 10 crore order
Mediaware Infotech offers new software
CCS Infotech bags BSNL Salem order
MoneyGram's expansion plans
Yamaha unveils Gladiator
Jagson Airlines buys two helicopters
XL Telecom files draft prospectus with SEBI
Joy Alukkas' fashion extravaganza
TVS Interconnect launches TVSnet
Accel Frontline to enter capital market
Nagarjuna bags international order
Kerala Property Expo in Doha
Ad club office bearers

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu